StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a report issued on Tuesday ...

Scott Braunstein, Chairman and CEO of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), recently executed several stock transactions, according to a filing with the Securities and Exchange Commission.

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

MARINUS PHARMACEUTICALS ($MRNS) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting ...

This marks Marius Pharmaceuticals’ fifth U.S. patent, further reinforcing its leadership in the field of testosterone replacement therapy. The newly allowed patent specifically covers the company’s ...

Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...

CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial, ...